Tb Alternative Assets LTD Cut By $10.83 Million Its Valeant Pharmaceuticals Inte Vrx Us (VRX) Stake; U.S. Physical Therapy, Inc. (USPH) Had 1 Bullish Analysts

May 24, 2018 - By Darrin Black

U.S. Physical Therapy, Inc. (NYSE:USPH) Logo

Among 5 analysts covering U.S. Physical Therapy (NYSE:USPH), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. U.S. Physical Therapy had 14 analyst reports since November 6, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained U.S. Physical Therapy, Inc. (NYSE:USPH) rating on Thursday, November 2. Cantor Fitzgerald has “Buy” rating and $74.0 target. The stock has “Buy” rating by Cantor Fitzgerald on Monday, July 24. The stock of U.S. Physical Therapy, Inc. (NYSE:USPH) earned “Hold” rating by Jefferies on Friday, August 4. Jefferies maintained U.S. Physical Therapy, Inc. (NYSE:USPH) rating on Friday, February 23. Jefferies has “Hold” rating and $76.0 target. The rating was downgraded by Barrington Research on Friday, November 6 to “Mkt Perform”. The stock of U.S. Physical Therapy, Inc. (NYSE:USPH) has “Neutral” rating given on Friday, May 4 by Cantor Fitzgerald. Jefferies maintained U.S. Physical Therapy, Inc. (NYSE:USPH) rating on Thursday, June 29. Jefferies has “Hold” rating and $6300 target. On Friday, March 17 the stock rating was downgraded by Barrington Research to “Market Perform”. The firm has “Outperform” rating by Barrington Research given on Friday, May 6. As per Friday, September 8, the company rating was upgraded by Sidoti. See U.S. Physical Therapy, Inc. (NYSE:USPH) latest ratings:

04/05/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Old Target: $72 Downgrade
23/02/2018 Broker: Jefferies Rating: Hold New Target: $76.0 Maintain

Tb Alternative Assets Ltd decreased Valeant Pharmaceuticals Inte Vrx Us (VRX) stake by 91.28% reported in 2017Q4 SEC filing. Tb Alternative Assets Ltd sold 541,500 shares as Valeant Pharmaceuticals Inte Vrx Us (VRX)’s stock declined 28.77%. The Tb Alternative Assets Ltd holds 51,700 shares with $1.07 million value, down from 593,200 last quarter. Valeant Pharmaceuticals Inte Vrx Us now has $7.75B valuation. The stock increased 0.77% or $0.17 during the last trading session, reaching $22.2. About 5.99M shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since May 24, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 have Buy rating, 5 Sell and 15 Hold. Therefore 29% are positive. Valeant Pharmaceuticals Intl had 169 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by BTIG Research on Thursday, May 11 with “Neutral”. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Overweight” rating given on Friday, June 16 by Cantor Fitzgerald. The firm has “Hold” rating by BMO Capital Markets given on Monday, October 30. The firm earned “Hold” rating on Thursday, November 9 by H.C. Wainwright. The stock has “Buy” rating by Bank of America on Wednesday, September 30. On Thursday, May 11 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Buy” rating given on Wednesday, June 8 by Stifel Nicolaus. On Wednesday, March 16 the stock rating was maintained by JP Morgan with “Overweight”. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Hold” rating by Deutsche Bank on Tuesday, September 20. The firm has “Underperform” rating given on Friday, February 19 by Wells Fargo.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: Seekingalpha.com which released: “Valeant: Much Ado About Nothing” on May 21, 2018, also 247Wallst.com with their article: “What Will Become of Valeant Pharmaceuticals?” published on May 08, 2018, Seekingalpha.com published: “Valeant Pharmaceuticals Can Still Go Higher – Cramer’s Lightning Round (5/21/18)” on May 22, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: Seekingalpha.com and their article: “Valeant Is Growing Once More” published on May 10, 2018 as well as Benzinga.com‘s news article titled: “Steve Sosnick’s Valeant Options Trade” with publication date: May 04, 2018.

Investors sentiment decreased to 0.97 in Q4 2017. Its down 0.02, from 0.99 in 2017Q3. It fall, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported. San Francisco Sentry Grp Inc (Ca) holds 0.04% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 6,300 shares. Baystate Wealth Mgmt Ltd Company has 149 shares. Aviva Pcl holds 0.02% or 189,499 shares. Greatmark Partners invested in 0.21% or 28,350 shares. Pictet Asset Mgmt reported 0.01% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). D E Shaw And Company Inc reported 638,072 shares. Amundi Pioneer Asset holds 0% or 89,191 shares. Goldman Sachs Gru invested 0.02% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Aqr Cap Mngmt Limited has invested 0.02% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Glenmede Trust Na reported 3,305 shares. Cambridge Research Advisors Inc holds 0% or 13,276 shares in its portfolio. 37,055 are owned by Nexus Invest Management. Amp Cap Investors owns 145,095 shares. Kazazian Asset Management Ltd Company reported 127,567 shares or 2.71% of all its holdings. Saba Cap Mgmt Lp reported 104,759 shares.

Since March 8, 2018, it had 4 insider purchases, and 0 insider sales for $1.20 million activity. Another trade for 10,000 shares valued at $153,400 was made by DE SCHUTTER RICHARD U on Thursday, March 8. Herendeen Paul also bought $241,470 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Tuesday, March 13. 30,000 shares were bought by PAPA JOSEPH C, worth $481,500.

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on August, 14. They expect $0.78 EPS, down 25.71% or $0.27 from last year’s $1.05 per share. VRX’s profit will be $272.44M for 7.12 P/E if the $0.78 EPS becomes a reality. After $0.89 actual EPS reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -12.36% negative EPS growth.

Since December 12, 2017, it had 0 buys, and 14 insider sales for $6.82 million activity. 12,000 shares were sold by READING CHRISTOPHER J, worth $1.04M on Friday, March 9. 1,179 U.S. Physical Therapy, Inc. (NYSE:USPH) shares with value of $98,175 were sold by McDowell Glenn. BROOKNER MARK J had sold 1,250 shares worth $114,788. PULLINS JERALD L sold $527,894 worth of stock or 6,100 shares. Trier Clayton sold 4,250 shares worth $305,873. MCAFEE LAWRANCE W sold $172,120 worth of stock or 2,000 shares. $519,153 worth of U.S. Physical Therapy, Inc. (NYSE:USPH) was sold by Harris Bernard A Jr.

The stock increased 0.21% or $0.2 during the last trading session, reaching $93.75. About 23,855 shares traded. U.S. Physical Therapy, Inc. (NYSE:USPH) has risen 26.09% since May 24, 2017 and is uptrending. It has outperformed by 14.54% the S&P500.

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics in the United States. The company has market cap of $1.19 billion. The Company’s clinics provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It has a 53.27 P/E ratio. As of December 31, 2016, the firm owned and operated 540 outpatient physical therapy clinics in 42 states; and managed 20 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts